BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started
https://doi.org/10.21518/2079-701X-2018-10-27-32
Abstract
Choice of the optimal therapy for BCLC-B hepatocellular carcinoma (HCC) is a significant clinical problem. Transarterial chemoembolisation (TACE) is considered to be the method of choice as this approach is reported to produce a direct effect and to have a significant survival rate. However, TACE is not always applicable and produce a survival benefit due to the clinical heterogeneity of BCLC-B HCC. The article includes different approaches for BCLC-B HCC patients, TACE prediction and refractory criteria as well as the results obtained. The necessity of timely sorafenib systemic therapy in BCLC-B and in advanced HCC after TACE is discussed. Practical application of regorafenib as the second line in HCC systemic treatment is discussed.
About the Authors
V. V. Breder
N.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
M. U. Pitkevich
N.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
E. R. Virshke
N.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
L. A. Kostyakova
N.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
I. A. Dzhanyan
N.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
K. K. Laktionov
N.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Siegel R et al. Cancer statistics, 2014. CA. Cancer J Clin, 2014. 64(1): 9–29.
2. Davydov MI, Axel EM. Statistics of malignant neoplasms in Russia and CIS countries in 2012. Izvestia Tinro, 2014. 226: 1-226.
3. Kaprin AD, Starinsky VV, Petrova GV. The state of cancer care in Russia in 2013. Herzen Moscow Cancer Research Institute of the Ministry of Health of Russia, 2014. 235 p.
4. Bruix J et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 2001, 35(3): 421–430.
5. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg, 1964, 1: 1–85.
6. Uehara T et al. Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicological sciences, 2013, 132(1): 53–63.
7. Breder VV. The strategy and tactics of conservative treatment of hepatocellular carcinoma, 2017.
8. Di Costanzo GG, Tortora R, Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol, 2015 May 28, 7(9): 1184-1191.
9. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma J Hepatol, 2018. Doi: 10.1016/j.jhep.2018.03.019.
10. Virshke ER, Kosyrev VYu, Dolgushin BI. Hepatocellular carcinoma, BCLC-B: in search of optimal treatment. Interventional radiological technologies in the treatment of patients with HCC. Zlokachestvennye Opukholi, 2016, 4 (special item 1): 26-28
11. Huppert P. Current concepts in transarterial chemoembolization of hepatocellular carcinoma. Abdom Imaging, 2011, 36(6): 677-683.
12. Aerts M et al. Current status and perspectives of immune-based therapies forhepatocellular carcinoma. World J Gastroenterol, 2016, 22(1): 253–261.
13. Ali MY et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol Elsevier, 2005, 43(5): 817–822.
14. Zerbini A et al. Radiofrequency Thermal Ablation of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance TumorSpecific T-Cell Responses. Cancer Res, 2006, 66(2).
15. Bolondi L et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions Semin Liver Dis, 2012, 32(4): 348–359.
16. Llovet JM et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002, 359(9319): 1734-9.
17. Terzi E et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed on demand. J Hepatol, 2012, 57(6): 1258-67.
18. Sieghart W et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology, 2013, 57: 2261–2273.
19. Kadalayil L et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol, 2013, 24(10): 2565–2570.
20. Hucke F et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol, 2014, 61(6): 1287-1296.
21. Arizumi T et al. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer, 2015 Dec, 4(4): 253–262.
22. Kudo M et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 Update by the liver cancer study group of Japan. Liver Cancer, 2014, 3(3–4): 458–468.
23. Raoul JL et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treatment Reviews, 2011: 212-220.
24. Colombo M et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med, 1991, 325: 675-680.
25. Ioannou GN et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol Elsevier, 2007, 5(8): 938–945, 945-4.
26. Cabibbo G et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol, 2012, 4(9): 256– 261.
27. Leung TWT et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res, 1999, 5(7): 1676– 1681.
28. Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4): 378-390.
29. Cheng A-L et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol Elsevier, 2009, 10(1): 25–3.
30. Iavarone M et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology, 2011, 54(6): 2055-63.
31. Ganten TM et al. Sorafenib in patients with hepatocellular carcinoma – results of the observational INSIGHT study. Clin Cancer Res, 2017, 23(19): 5720–5728.
32. Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin Investig Drugs, 2012, 21(6): 879–889.
33. Bruix J et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2016, 0(0): 1020–1022.
34. Finn RS et al. Proc ASCO GI. San Francisco, USA, 19–21 Jan 2017, abstract 344.
35. Lencioni R. Chemoembolization in Patients with Hepatocellular Carcinoma. Liver Cancer, 2012, 1(1): 41–50.
36. Meyer T et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol, 2017, 2: 565–75.
37. Kudo M et al. Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. J Clin Oncol, 2018, 36(suppl, abstr 4017).
Review
For citations:
Breder VV, Pitkevich MU, Virshke ER, Kostyakova LA, Dzhanyan IA, Laktionov KK. BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started. Meditsinskiy sovet = Medical Council. 2018;(10):27-32. (In Russ.) https://doi.org/10.21518/2079-701X-2018-10-27-32
Views:
644
Email this article 